Understand the source comparison
Research Peptides for REM Sleep Issues: Detailed Compound Comparison
DSIP Binds delta sleep-inducing factor receptors in hypothalamus None. Increases slow-wave sleep without affecting REM latency or percentage 0.5–2 mg subcutaneous before sleep Oxidises rapidly above 8°C; lyophilised form stable 24 months at −20°C Best for NREM
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- Binds delta sleep-inducing factor receptors in hypothalamus
- None. Increases slow-wave sleep without affecting REM latency or percentage
- 0.5–2 mg subcutaneous before sleep
- Oxidises rapidly above 8°C; lyophilised form stable 24 months at −20°C
- Best for NREM architecture research. Does not modulate REM directly
- Epithalon
- Upregulates telomerase in pineal gland, restoring melatonin synthesis
- Improves REM bout duration and reduces REM fragmentation by normalising circadian amplitude
- 5–10 mg subcutaneous, 10–20 day cycles
- Moderate. Deamidation occurs in aqueous solution; reconstituted form stable 21–28 days at 4°C
- Best for circadian-driven REM disruption; works upstream of sleep architecture
- Thymosin Beta-4
- Reduces IL-6 and TNF-alpha via NF-kappaB inhibition
- Reduces REM fragmentation by lowering arousal thresholds caused by inflammatory cytokines
- 2–5 mg subcutaneous 2–3×/week
- Moderate. Methionine residues oxidise in presence of peroxides; lyophilised form stable 18 months at −20°C
- Best for inflammation-driven sleep fragmentation; indirect REM benefit
- Selank
- Modulates GABA and enkephalin systems; anxiolytic without sedation
- Minimal direct REM effect; reduces pre-sleep arousal that delays REM onset
- 250–500 mcg intranasal
- High. Acetylated N-terminus resists enzymatic degradation; stable 12 months at 4°C
- Best for anxiety-driven REM latency延長; does not alter REM architecture directly